一种治疗奶牛阴道炎症微生态制剂的临床药效学研究

为检验约氏乳杆菌SQ0048菌株所制备的微生态制剂对临床型奶牛阴道炎症的治疗作用,将其应用于患有阴道炎的病牛体内,利用临床兽医学方法观察给药前后患牛的临床症状,采用变性梯度凝胶电泳法检测给药前后患牛阴道内的微生物菌群种属,使用酶联免疫吸附技术检测给药前后患牛血清内细胞因子分泌量。结果显示,此微生态制剂不仅可以缓解临床奶牛阴道炎性症状,提高发情率及受胎率,还可以减少或杀灭阴道内的利氏卟啉单胞菌、铜绿假单胞菌、化脓隐秘杆菌及链球菌等,增加约氏乳杆菌SQ0048菌株及谷氨酸棒状杆菌的数量,改善阴道微生态环境,维持阴道的微生态平衡;同时给药后患牛血清中IL-1β、IL-6、IFN-α、TNF-α分泌量显著低于给药前,而IL-10分泌量则显著高于给药前,具有一定抑制炎症的生物学功能。     

林可霉素水溶性粉剂对由魏氏梭菌引起的鸡坏死性肠炎的药效研究

本文对新兽药制剂林可霉素水溶性剂，用人工感染发病的方法进行了药效学研究。     

Oral Cyclosporine Treatment in Dogs: A Review of the Literature

Cyclosporine is an immunomodulatory drug used to treat an increasing spectrum of diseases in dogs. Cyclosporine is a calcineurin inhibitor, ultimately exerting its inhibitory effects on T‐lymphocytes by decreasing production of cytokines, such as interleukin‐2. Although, in the United States, oral cyclosporine is approved in dogs only for treatment of atopic dermatitis, there are many other indications for its use. Cyclosporine is available in 2 oral formulations: the original oil‐based formulation and the more commonly used ultramicronized emulsion that facilitates oral absorption. Ultramicronized cyclosporine is available as an approved animal product, and human proprietary and generic preparations are also available. Bioavailability of the different formulations in dogs is likely to vary among the preparations. Cyclosporine is associated with a large number of drug interactions that can also influence blood cyclosporine concentrations. Therapeutic drug monitoring (TDM) can be used to assist in attaining consistent plasma cyclosporine concentrations despite the effects of varying bioavailability and drug interactions. TDM can facilitate therapeutic success by guiding dose adjustments on an individualized basis, and is recommended in cases that do not respond to initial oral dosing, or during treatment of severe, life‐threatening diseases for which a trial‐and‐error approach to dose adjustment is too risky. Pharmacodynamic assays that evaluate individual patient immune responses to cyclosporine can be used to augment information provided by TDM.     

单诺沙星对鸡败血支原体与大肠杆菌合并感染的药效学研究

采用试管二倍稀释法测得单诺沙星及其对照药物恩诺沙星、泰乐菌素对鸡败血支原体（MG）的最低抑菌浓度分别为0．0625、0.125、0.5mg/L。试验鸡每只左右气囊分别接种MG S6株菌液0.75ml、滴鼻约0.3ml，同时腹腔注射大肠杆菌菌液0.3ml,人工诱发鸡败血支原体与大肠杆菌合并感染的疾病模型。25、50、100mg/L的单诺沙星、500mg／L的恩诺沙星和500mg/L的泰乐菌素连续饮水5d给药，对人工合并感染鸡败血支原体与大肠杆菌病的治愈率分别为93.3%、96.6%、96.6%、93.3%、86.6%，而感染对照组的死亡率为23.3％。单诺沙星及其对照药物组的增重率显著高于感染对照组，并能极显著的降低感染鸡的死亡率、抗体反应阳性率、气囊损伤率及病原再分离率。     

环丙沙星对实验性猪支原体性肺炎的药效学研究

测定环丙沙星及对照药物对猪肺炎支原体的最小抑菌浓度，其中环丙沙星的抗支原体活性最强，最小抑菌浓度为0．01μg/ml。通过给18头健康猪气管内接种含有猪肺炎支原体的病肺悬液，复制具有典型症状的猪支原体性肺炎疾病模型，并进行环丙沙星2．5、5．0mg/kg肌注给药对实验性猪支原体性肺炎的疗效实验及血浆药物浓度监测，两组治愈率分别为83．3％（5／6）和100％（6／6）。治疗组多剂量给药期间，第1、3、5、7、9次给药后0．5及6h的血浆药物浓度，在2．5mg/kg剂量组平均为0．41μg/ml和0．17μg/ml,5.0mg/kg剂量组平均为0．71μg/ml和0．28μg/ml。两剂量组环丙沙星均无蓄积作用。     

Comparative pharmacokinetics of marbofloxacin in healthy and Mannheimia haemolytica infected calves

The pharmacokinetics of marbofloxacin were investigated in healthy (n=8) and Mannheimia haemolytica naturally infected (n=8) Simmental ruminant calves following intravenous (i.v.) and intramuscular (i.m.) administration of 2 mg kg(-1) body weight. The concentration of marbofloxacin in plasma was measured using high performance liquid chromatography with ultraviolet detection. Following i.v. administration of the drug, the elimination half-life (t(1/2 beta)) and mean residence time (MRT) were significantly longer in diseased calves (8.2h; 11.13 h) than in healthy ones (4.6 h; 6.1 h), respectively. The value of total body clearance (CL(B)) was larger in healthy calves (3 ml min(-1) kg(-1)) than in diseased ones (1.3 ml min(-1) kg(-1)). After single intramuscular (i.m.) administration of the drug, the elimination half-life, mean residence time (MRT) and maximum plasma concentration (C(max)) were higher in diseased calves (8.0, 12 h, 2.32 microg ml(-1)) than in healthy ones (4.7, 7.4 h, 1.4 microg ml(-1)), respectively. The plasma concentrations and AUC following administration of the drug by both routes were significantly higher in diseased calves than in healthy ones. Protein binding of Marbofloxacin was not significantly different in healthy and diseased calves. The mean value for MIC of marbofloxacin for M. haemolytica was 0.1+/-0.06 microg ml(-1). The C(max)/MIC and AUC(24)/MIC ratios were significantly higher in diseased calves (13.0-64.4 and 125-618 h) than in healthy calves (8-38.33 and 66.34-328 h). The obtained results for surrogate markers of antimicrobial activity (C(max)/MIC, AUC/MIC and T > or = MIC) indicate the excellent pharmacodynamic characteristics of the drug in diseased calves with M. haemolytica, which can be expected to optimize the clinical efficacy and minimize the development of resistance.     

二氟沙星对实验性感染猪支原体性肺炎及链球菌病的药效学研究

以试管两倍稀释法测得二氟沙星对猪肺炎支原体（ Ｆ１６ 株）和兰氏 Ｃ 群类马链球菌（ Ｃ５５ １ ２０ ）的最小抑菌浓度分别是０１６ｍ ｇ／ Ｌ及 １６ｍ ｇ／ Ｌ。肌注给药对猪支原体性肺炎及链球菌病的实验性治疗结果表明,低、中、高剂量二氟沙星组（２５、５、１０ｍ ｇ／ｋｇ）及蒽诺沙星组（２５ｍ ｇ／ｋｇ）用药 ５ 天（每隔 １２ 小时给药一次）对猪支原体性肺炎的治愈率分别是 ８０％ 、９０％ 、１００％ 及９０％ ;而支原体感染对照组的自愈率为１０％ 。低、中、高剂量二氟沙星组及蒽诺沙星组（２５ｍ ｇ／ｋｇ）用药 ４ 天（每隔 １２ 小时给药一次）对猪链球菌病的治愈率分别是 ５０％ 、８０％ 、８０％ 及 ８０％ ,而链球菌感染对照组的死亡率为 ５０％ 。     

内酯类新抗生素泰拉霉素的研究进展

泰拉霉素是动物专用半合成大环内酯类抗生素,对于防治猪和牛的呼吸系统疾病疗效确切。从泰拉霉素的理化性质、作用机制、抗菌活性、药动学和药效学、急慢性毒性及药物残留等方面进行综述,旨在为该药在兽医临床应用提供参考资料。     

氟苯尼考双混悬型乳剂的体外药效学研究(英文)

[目的]为了探明氟苯尼考双混悬型乳剂的体外药效学特征。[方法]以氟苯尼考注射液为对照组对氟苯尼考双混悬型乳剂进行5种细菌的最低抑菌浓度(MIC)、最低杀菌浓度(MBC)和耐药突变选择窗(MSW)的测定,对鼠伤寒沙门氏菌进行抗生素后效应(PAE)和抗生素后亚抑菌浓度效应(PASME)的测定。[结果]相对于普通注射液氟苯尼考双混悬型乳剂对5种细菌的MIC和MBC无明显变化,但其明显缩小了对5种细菌的MSW(P<0.01),并且明显的延长了对鼠伤寒沙门氏菌PAE和PASME(P<0.01)。[结论]氟苯尼考双混悬型乳剂在体外能够减小细菌耐药几率,明显延长抗生素对细菌的后效应时间,从而有效地提高抗菌效果。     

复方生血灵促生血机制及药效学研究

本文对复方生血灵的促生血机制及药效学进行了研究，结果表明，复方生血灵具有促进小鼠骨髓细胞ＤＮＡ，ＲＮＡ合成，促进骨髓造血机能和抗辐射作用对贫血病有良好的疗效。